2021-07-15
Today, Camurus' interim report for the second quarter 2021 was published. "It was a positive second quarter with significant progress on key objectives with increasing revenues, new regulatory approvals, and a potential US market authorization in 2021", says Fredrik Tiberg, President &CEO.
Read the full report on Camurus' website: www.camurus.com
2020-07-16
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”
Read more2020-06-24
Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…
Read more2020-06-23
The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…
Read more2020-05-07
”The number of patients treated with Buvidal® increased by 90 percent in the quarter”
Read more2020-04-08
Camurus Annual Report for 2019 is now available at the company´s website.
Read more